Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
105 hedge funds and large institutions have $115M invested in Paratek Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 19 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
9% less funds holding
Funds holding: 116 → 105 (-11)
30% less capital invested
Capital invested by funds: $164M → $115M (-$49M)
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
57% less call options, than puts
Call options by funds: $601K | Put options by funds: $1.41M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.78M |
| 2 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
+$1.99M |
| 3 |
BC
Bruce & Co
Chicago,
Illinois
|
+$992K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$871K |
| 5 |
TI
Telemetry Investments
New York
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.25M |
| 2 |
Renaissance Technologies
New York
|
-$1.25M |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$1.22M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.12M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.07M |
PRTK Hedge Fund Activity: Q3 2021 in Review
105 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2021, worth a combined $115M — down 30% from $164M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PRTK and 10 opened new positions — a net loss of 9 holders — while 33 trimmed existing stakes and 39 added.
The largest buyer was AIGH Capital Management, adding an estimated $3.78M. The largest seller was Millennium Management, cutting an estimated $1.25M.
- 105 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2021, down from 116 in Q2 2021.
- Funds reported $115M of Paratek Pharmaceuticals, Inc. stock for Q3 2021, down 30% quarter-over-quarter.
- 10 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2021 and 19 closed out, a net change of -9 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2021 was AIGH Capital Management, an estimated $3.78M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2021 was Millennium Management, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2021.